{Reference Type}: Letter
{Title}: Letter to editor: Comment on "Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma with and without NOTCH signaling pathway activation".
{Author}: Sudhakaran G;
{Journal}: Oral Oncol
{Volume}: 156
{Issue}: 0
{Year}: 2024 Sep 13
{Factor}: 5.972
{DOI}: 10.1016/j.oraloncology.2024.106953
{Abstract}: The study by Feeney et al. provides critical insights into the prognostic implications of NOTCH pathway activation in adenoid cystic carcinoma (ACC), particularly after disease recurrence. Utilizing both next-generation sequencing and immunohistochemistry, the research delineates the survival outcomes between NOTCH-activated and non-activated ACC groups, highlighting poorer outcomes in the former. The findings advocate for the targeted therapeutic approach and suggest a potential for personalized treatment strategies, emphasizing the need for further research into NOTCH pathway inhibitors and their clinical applications.